Madrigal Pharma
MDGL487.94010.78% ( -58.940 )
Q1 FY2026 EarningsQ2 FY26 revenue reached $364.3M, up 71.2% YoY, driven by strong Rezdiffra® adoption with over 49,000 active patients. Net loss widened to $57.9M ($1.99 per share), impacted by a one-time $25M R&D business development expense. Cash reserves remain robust at $838.9M, supporting the launch and pipeline expansion including the new Phase 1 MGL-2086 program.
Financial report interval: 2025.12.31 - 2026.03.31
Preview: Madrigal Pharma(MDGL) predict that the Revenue is 311.34 M (+126.8%), Beat estimate;the EBIT is -92.72 M (-16.91%), Beat estimate;the EPS is -3.25 (+2.11%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.31B126.84%
0.30B119.25%
+0.01B7.59%
EBITExceed expectations
-0.09B16.91%
-0.10B24.50%
+0.01B7.59%
EPSExceed expectations
-3.252.11%
-4.042521.76%
+0.792523.87%
Upcoming earnings report - FY2026 Q2 Earning Release
Available dateJul 30, 2026
Estimate Revenue353.17 M
Estimate EBIT-78.16 M
Estimate EPS-2.6404
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf